Linked Life Data

1166824

Source:http://linkedlifedata.com/resource/pubmed/id/1166824

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
1975-12-11
pubmed:abstractText
From a survey of 1250 males, 40-60 years of age, 25 mildly to moderately hypertensive patients have been offered treatment with the new beta-blocker ICI 66.082. Before and during the trial, data were obtained on resting BP and pulse rate, BP, pulse rate and ECGs during near maximal exercise, and various ventilatory function tests. In 15 patients, satisfactory BP control was obtained with ICI 66.082 alone, 25-100 mg twice daily. In 5 patients, the addition of hydralazine or a diuretic was necessary for satisfactory response. In 2 patients satisfactory control was not achieved and 3 patients were excluded for various reasons. Although BP and maximal pulse rate fell markedly during exercise, the total work capacity was not significantly reduced. No deleterious effect on ventilatory function was noted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0001-6101
pubmed:author
pubmed:issnType
Print
pubmed:volume
198
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
49-53
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
A trial of a new adrenergic beta-receptor blocker, ICI 66.082, in the treatment of hypertension.
pubmed:publicationType
Journal Article